News for Foghorn Therapeutics Inc. (FHTX)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Shares of PVH Corp. PVH rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Calvin Kle...

Shares of PVH Corp. PVH rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Calvin Kle...

**media[576518]**

Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the

[url=

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -3.45% and 75.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

On December 31, 2024, FMR LLC (Trades, Portfolio) executed a strategic transaction involving Foghorn Therapeutics Inc (FHTX), reducing its stake by 644,265 shar

Foghorn Therapeutics (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Foghorn Therapeutics (FHTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

First-in-class oral selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784), advancing in Phase 1 trial for SMARCA4 mutated cancers, with non-small cell lung can

Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Foghorn Therapeutics Inc. (FHTX), Monday said that it decided to discontinue the development of FHD-286 in combination with decitabine to treat patients with acute myeloid leukemia (AML).

**media[493316]**

The heavy selling pressure might have exhausted for Foghorn Therapeutics (FHTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 104.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.